60
Participants
Start Date
December 10, 2024
Primary Completion Date
January 31, 2027
Study Completion Date
April 30, 2027
TP04HN106
During the treatment period, the experimental drug group received intravenous injections of 0.83mL/kg TP04HN106 each time; During the extension period, all subjects received intravenous injection of 0.83mL/kg TP04HN106.
Saline
The placebo group received intravenous injections of 0.83mL/kg of saline each time. In the experiment, all subjects received Liraglutide tablets as the standard baseline treatment.
RECRUITING
The First Affiliated Hospital of Soochow University, Suzhou
The First Affiliated Hospital of Soochow University
OTHER
Talengen Institute of Life Sciences, Shenzhen, P.R. China.
OTHER